Business Context and Reporting Period
Company: Mobix Labs, Inc. (MOBX)
Filing Type: Form 8-K (Current Report)
Date of Report: July 22, 2024
Event: Entry into a Material Definitive Agreement for a Private Placement (PIPE) with an institutional accredited investor.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $4.0 million (before fees and expenses).
- Securities Issued:
- Pre-Funded Warrants: 2,877,698 units exercisable for Class A Common Stock at $0.001 per share.
- PIPE Common Warrants:
- Series A: 2,877,698 warrants exercisable at $1.39 per share; expire 5 years after stockholder approval.
- Series B: 2,877,698 warrants exercisable at $1.39 per share; expire 12 months after stockholder approval.
- Placement Agent Fees:
- Cash fee: 7.0% of gross proceeds.
- Management fee: 1.0% of gross proceeds.
- Non-accountable expenses: $85,000.
- Warrants: 201,439 Placement Agent Warrants (7.0% of Pre-Funded Warrants) at $1.7375 per share.
- Use of Proceeds: Working capital, potential future acquisitions, and associated operational expenses.
Material Changes and Agreements
The filing details a significant capital raise via a private placement. Key contractual obligations include:
- Stockholder Approval: The Company must obtain stockholder approval for the issuance of shares underlying the PIPE Common Warrants within 90 days of closing. If not obtained initially, meetings must be called every 90 days thereafter until approval is secured.
- Registration Rights: The Company must file a registration statement for the resale of warrant shares by August 13, 2024, and use best efforts to have it declared effective within 60 days (or 90 days if a full SEC review is required).
- Lock-Up Agreement: Directors and officers are restricted from selling or pledging their Common Stock for 90 days after the effectiveness of the Registration Statement.
- Beneficial Ownership Limitation: Exercise of Pre-Funded Warrants is capped if it would cause the holder to beneficially own more than 9.99% of outstanding shares, unless notice is given to increase this limit (subject to a 61-day waiting period).
Guidance, Risks, and Contingencies
- Contingency on Approval: The exercisability of the PIPE Common Warrants is contingent upon stockholder approval. Until then, these warrants cannot be exercised.
- Unregistered Securities: The PIPE Securities were issued under Section 4(a)(2) and Regulation D exemptions and have not been registered under the Securities Act. They cannot be resold in the U.S. absent registration or an applicable exemption.
- Future Dilution: The transaction introduces significant potential dilution through the issuance of Pre-Funded Warrants and two series of Common Warrants.
- Management Commentary: The filing does not provide specific forward-looking financial guidance beyond the stated use of proceeds for working capital and acquisitions.
Investor Verification Checklist
- Verify the status of the Registration Statement filing deadline (August 13, 2024) and its subsequent effectiveness.
- Monitor the timeline for the required stockholder meeting to approve the PIPE Common Warrants (must occur within 90 days of closing).
- Review the definitive forms of the Securities Purchase Agreement and Warrants (Exhibits 10.1, 4.1, 4.2, 4.3, 4.4) for specific redemption or anti-dilution provisions not summarized here.
- Confirm the identity of the institutional accredited investor, as it is not named in the summary text.
- Assess the impact of the 9.99% beneficial ownership limitation on the immediate liquidity of the Pre-Funded Warrants.